Dosimetry and Radiation Safety of [ 177 Lu] Lu-PSMA-617 in End-Stage Renal Disease on Hemodialysis: A Three-Cycle Case (EANM 2026) - Sep 29, 2026 - Abstract #EP-1034; "[¹⁷⁷Lu] Lu-PSMA-617 was feasible in this hemodialysis-dependent patient and enabled detailed ESRD-specific dosimetry. Absorbed-dose patterns differed from standard trial populations, particularly for spleen and marrow, supporting dialysis-integrated dosimetry and close hematologic monitoring in this underrepresented group."
Clinical • Castration-Resistant Prostate Cancer • Chronic Kidney Disease • Dental Disorders • Genito-urinary Cancer • Hematological Malignancies • Nephrology • Prostate Cancer • Renal Disease • Solid Tumor • Thrombocytopenia • Xerostomia
|
|
A. Al-Balushi; K. Al-Riyami; N. Al-Maymani; H. Al-Saidi; T. Al-Raii; S. Kheruka; A. Al-Busaidi; A. Jain; N. Al-Makhmari; S. Al-Rashdi; S. Usmani
|